Advicenne (Euronext Growth Paris:ALDVI), a specialty pharmaceutical company focused on rare renal diseases, announced on Tuesday that it has secured key regulatory milestones for its ADV7103 drug in the United States.
The US Food and Drug Administration (FDA) has said that European clinical data can be used to support an application for registration in dTRA (Distal Renal Tubular Acidosis) without further clinical trials.
Additionally, the positive orphan drug designation in cystinuria has paved the way for productive discussions with the FDA on development in this indication.
These advancements are poised to bolster Advicenne's partnership prospects for commercialising ADV7103 in the US. The company has already garnered interest from potential partners in the region.
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
hVIVO reports positive results from RSV antiviral human challenge trial
Amyris enters agreement with BioMaP-C
Avidity Biosciences reports partial clinical hold on delpacibart etedesiran lifted
UroGen Pharma doses first patient in Phase 3 trial of UGN-103 for bladder cancer
Brain+ launches Ayla CST Assistant following UK regulatory approval
Advicenne's ADV7103 achieves regulatory milestones in the US
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment